ATE512671T1 - Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs - Google Patents

Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs

Info

Publication number
ATE512671T1
ATE512671T1 AT05007380T AT05007380T ATE512671T1 AT E512671 T1 ATE512671 T1 AT E512671T1 AT 05007380 T AT05007380 T AT 05007380T AT 05007380 T AT05007380 T AT 05007380T AT E512671 T1 ATE512671 T1 AT E512671T1
Authority
AT
Austria
Prior art keywords
laminin receptor
diagnostics
antibodies
cancer
precursor
Prior art date
Application number
AT05007380T
Other languages
English (en)
Inventor
Melvyn Little
Stefan Knackmuss
Uwe Reusch
Sergey Kipriyanov
Gall Fabrice Le
Vera Mick
Karin Hoffmann
Peter Roettgen
Stefan Weiss
Original Assignee
Affimed Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics Ag filed Critical Affimed Therapeutics Ag
Application granted granted Critical
Publication of ATE512671T1 publication Critical patent/ATE512671T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05007380T 2005-04-05 2005-04-05 Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs ATE512671T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007380A EP1709972B1 (de) 2005-04-05 2005-04-05 Verwendung von Antikörpern gegen den Lamininrezeptor oder den Lamininrezeptorvorläufer zur Diagnose von Krebs

Publications (1)

Publication Number Publication Date
ATE512671T1 true ATE512671T1 (de) 2011-07-15

Family

ID=34979018

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05007380T ATE512671T1 (de) 2005-04-05 2005-04-05 Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs

Country Status (6)

Country Link
US (1) US7901677B1 (de)
EP (1) EP1709972B1 (de)
AT (1) ATE512671T1 (de)
AU (1) AU2006232836B2 (de)
CA (1) CA2603480A1 (de)
WO (1) WO2006105954A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115601A1 (en) * 2007-03-22 2008-09-25 The Johns Hopkins University 67lr antibodies and their uses in the treatment of cancer
DE102007041834A1 (de) * 2007-09-03 2009-03-05 Siemens Ag Arzneimittel zur Behandlung eines Karzinoms
JP7308505B2 (ja) * 2016-01-08 2023-07-14 マキシオン セラピューティクス リミテッド 多様性を変化させた足場ドメインを有する結合メンバー
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
EP3882272B1 (de) * 2018-09-17 2024-11-06 Zymedi Co., Ltd. Antikörper zur spezifischen bindung an eine gegenüber der extrazellulären membran exponierte n-terminale domäne der lysyl-trna-synthetase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
EP1442062A4 (de) * 2001-10-18 2005-11-09 Genentech Inc Verfahren zur behandlung von karzinomen
DE10346627A1 (de) * 2003-10-08 2005-05-19 Weiss, Stefan, PD Dr. Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
AU2006232836A1 (en) 2006-10-12
US7901677B1 (en) 2011-03-08
WO2006105954A2 (en) 2006-10-12
EP1709972B1 (de) 2011-06-15
AU2006232836B2 (en) 2012-05-31
EP1709972A1 (de) 2006-10-11
CA2603480A1 (en) 2006-10-12
WO2006105954A3 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
ATE509033T1 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
ATE517183T1 (de) Monoklonaler antikörper gegen cd20
MX2009009450A (es) Anticuerpos monoclonales para he4 y metodos para su uso.
EA201001874A1 (ru) Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты
WO2006084092A3 (en) Antibodies to oncostatin m receptor
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
EP2210939A4 (de) Anti-bst2-antikörper
ATE441116T1 (de) Verfahren zur selektiven bestimmung von procalcitonin 1-116 für diagnostische zwecke sowie antikírper und kits zur ausführung dieses verfahrens
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
MY182750A (en) Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
WO2008025964A3 (en) Antibodies to an epitope of agr2. assays and hybridomas
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
WO2011064257A3 (de) Monospezifische polypeptidreagenzien
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
UA108349C2 (uk) Гуманізоване антитіло з протипухлинною активністю
ATE512671T1 (de) Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs
MX343873B (es) Ensayo de diagnostico de anticuerpo.
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
FI20012603A0 (fi) Diagnostinen menetelmä
WO2008120006A3 (en) Diagnostic assay
WO2010053772A3 (en) Disease-associated antigens and methods of use thereof
ITRM20040098A1 (it) Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties